Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2025

Conditions
Breast CancerEndometrial Hyperplasia and Endometrial Cancers
Interventions
DRUG

Metfomin

Metformin Tab. 500mg twice daily for 12 months (titrated to tolerance if needed).

DRUG

tamoxifen

Standard prescribed oncological dose.

DRUG

Placebo matching Metformin

"An inert, film-coated tablet identical in appearance and packaging to metformin 500 mg (same size, shape, color, coating, weight, and dosing schedule), manufactured without active ingredient using standard excipients (e.g., microcrystalline cellulose, starch/croscarmellose, povidone, magnesium stearate) and identical film coat (e.g., hypromellose, polyethylene glycol, titanium dioxide). Packaged in sealed blisters to minimize odor/taste cues. Dispensed by the investigational pharmacy per randomization; to be taken twice daily"

Trial Locations (1)

10045

Baghdad Medical City / Department of Oncology, Baghdad

All Listed Sponsors
lead

Uruk University

OTHER

NCT07145827 - Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen | Biotech Hunter | Biotech Hunter